Publication:
COVID-19 vaccination in pregnancy

dc.contributor.coauthorHeath, P.
dc.contributor.coauthorPrasad, S.
dc.contributor.coauthorO Brien, P.
dc.contributor.coauthorKhalil, A.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorKalafat, Erkan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T12:20:09Z
dc.date.issued2022
dc.description.abstractDespite a recent endorsement from official and professional bodies unequivocally recommending COVID-19 vaccination, vaccine hesitancy among pregnant people remains high. The accumulated evidence demonstrates that pregnant people are a special risk group for COVID-19, with an increased risk of intensive care unit admission, extracor-poreal membranous oxygenation requirement, preterm birth, and perinatal death. These risks are further increased with some variants of concern, and vaccination of pregnant people reduces the COVID-19-related increase in maternal or fetal morbidity. Data from more than 180,000 vaccinated persons show that immunization against COVID-19 with an mRNA vaccine is safe for pregnant people. Many observational studies comparing perinatal outcomes between vaccinated and unvaccinated pregnant people have had reassuring findings and did not demonstrate harmful effects on pregnancy or the newborn. Immunization with mRNA vaccines does not increase the risk of miscarriage, preterm delivery, low birthweight, maternal or neonatal intensive care unit admission, fetal death, fetal abnormality, or pulmonary embolism. Moreover, observational data corroborate the findings of randomized trials that mRNA vaccination is highly effective at preventing severe SARS-CoV-2 infection in pregnant people, emphasizing that the potential maternal and fetal benefits of vaccination greatly outweigh the potential risks of vaccination. Ensuring pregnant people have unrestricted access to COVID-19 vaccination should be a priority in every country worldwide.
dc.description.fulltextYES
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue2
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume227
dc.identifier.doi10.1016/j.ajog.2022.05.020
dc.identifier.eissn1097-6868
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR03701
dc.identifier.issn0002-9378
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-85132236567
dc.identifier.urihttps://doi.org/10.1016/j.ajog.2022.05.020
dc.identifier.wos836681800007
dc.keywordsAntibodies
dc.keywordsCOVID-19
dc.keywordsImmunogenicity
dc.keywordsMaternal immunization
dc.keywordsPandemic
dc.keywordsPregnancy
dc.keywordsReactogenicity
dc.keywordsSARS-CoV-2
dc.keywordsSide effects
dc.keywordsVaccine
dc.language.isoeng
dc.publisherElsevier
dc.relation.grantnoNA
dc.relation.ispartofAmerican Journal of Obstetrics and Gynecology.
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10556
dc.subjectObstetrics and gynecology
dc.titleCOVID-19 vaccination in pregnancy
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorKalafat, Erkan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10556.pdf
Size:
913.06 KB
Format:
Adobe Portable Document Format